Chronic graft-versus-host disease (cGVHD) is a leading cause of late morbidity and mortality following allogeneic stem cell transplantation. Current therapies, including corticosteroids and calcineurin inhibitors, are only effective in roughly 50% of cases; therefore, new treatment strategies are under investigation. What was previously felt to be a T cell disease has more recently been shown to involve activation of both T and B cells, as well as a number of cytokines. With a better understanding of its pathophysiology have come more expansive preclinical and clinical trials, many focused on B cell signaling. This report briefly reviews our current understanding of cGVHD pathophysiology and reviews clinical and preclinical trials with B cell-targeted agents.
Recommended CitationRhoades, MD, Ruben and Gaballa, MD, Sameh, "The Role of B Cell Targeting in Chronic Graft-Versus-Host Disease." (2017). Department of Medical Oncology Faculty Papers. Paper 74.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.